Why the study?
Excessive visceral adipose tissue is linked to increased pro-inflammatory molecule secretion, systemic inflammation, and obesity-related metabolic disturbances.
Is a reduction in visceral adipose tissue associated with improved inflammatory and adiposity markers in overweight/obese adults with metabolic syndrome?
Is a reduction in visceral adipose tissue associated with improved inflammatory and adiposity markers in overweight/obese adults with metabolic syndrome?
Reduction in visceral adipose tissue is associated with improvements in inflammatory and adiposity markers, which may reduce cardiometabolic disturbances in obesity.
VAT increases may worsen metabolic/inflammatory profiles in metabolic syndrome; leaves open whether reduction improves outcomes.
SCOPE: Excessive visceral adipose tissue (VAT) is associated with higher secretion of pro-inflammatory molecules, contributing to systemic inflammation and obesity-related metabolic disturbances. METHODS AND RESULTS: This prospective analysis includes 117 overweight/obese adults (55-75 years) from the PREDIMED-Plus study. Fourteen inflammatory markers and adipokines are measured using a Bio-Plex assay with multiplex technology: insulin, glucagon, IL-6, visfatin, ghrelin, GLP-1, TNF-α, MCP-1, PAI-1, resistin, C-peptide, leptin, adipsin, and adiponectin. Participants are categorized into tertiles according to changes in VAT after 1-year of follow-up, determined by dual-energy X-Ray absorptiometry. Participants allocate in tertile 3, which represent an increase of VAT content after 1-year of follow-up compared to tertile 1, show significant differences in insulin (T3 vs T1, fully adjusted model: p = 0.037, p for trend 0.042), PAI-1 (fully adjusted model: p = 0.05, p for trend 0.06), c-peptide (fully adjusted model: p = 0.037, p for trend 0.042), and TNF-α (fully adjusted model p = 0.037, p for trend 0.042). CONCLUSION: The results evidence that a reduction in VAT is associated with clinical improvements in several inflammatory and adiposity markers, mainly in insulin, c-peptide, and PAI-1 levels, and these improvements may contribute to a reduction in cardiometabolic disturbances observe in obesity.
No takes yet. Share an insight, caveat, or question.
Castro‐Barquero et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: